• BioMarin Pharmaceutical Inc., of Novato, Calif., said it started a Phase I study in healthy volunteers for BMN-111, an analogue of C-type natriuretic peptide in development for achondroplasia. The trial is a two-part study designed to test single and multiple subcutaneous doses of the drug in up to 74 subjects. Data are expected in the third quarter of this year.